The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EBMT 2017 | Is autologous stem cell transplantation still the backbone of multiple myeloma treatment?
Nicolaus Kröger, MD, from the University Medical Center Hamburg-Eppendorf, Hamburg, Germany, discusses developments in multiple myeloma (MM) and how novel agents can be integrated into transplant at the 2017 annual meeting of the European Society for Blood and Marrow Transplantation (EBMT) in Marseille, France. Dr Kröger explains that there are now many novel agents for MM and many options to treat patients. While autologous stem cell transplantation remains a key option, he explains that the field is improving as the question is not whether novel agents are used, but in which combinations they are used to achieve a complete or deep remission. This is important as patients who achieve this complete remission have a good chance of a long-term progression free survival.
